IFNAR1 and neoplasm: For the first time in our combination studies with VSV administered 6 h prior to CAR T cells, we observed a reduced tumor growth rate and a significant extension of survival in lymphodepleted mice which received both IFNAR1 KO CAR T cells and three doses of VSVmIFNβ compared to those animals which only received CAR T cells (Fig. 6f).